WO2011051948A2 - Compositions de soins capillaires et matériaux - Google Patents

Compositions de soins capillaires et matériaux Download PDF

Info

Publication number
WO2011051948A2
WO2011051948A2 PCT/IL2010/000903 IL2010000903W WO2011051948A2 WO 2011051948 A2 WO2011051948 A2 WO 2011051948A2 IL 2010000903 W IL2010000903 W IL 2010000903W WO 2011051948 A2 WO2011051948 A2 WO 2011051948A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
inhibitors
copper oxide
textile
hair
Prior art date
Application number
PCT/IL2010/000903
Other languages
English (en)
Other versions
WO2011051948A3 (fr
Inventor
Jeffrey S. Gabbay
Original Assignee
Cupron Scientific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cupron Scientific Ltd filed Critical Cupron Scientific Ltd
Publication of WO2011051948A2 publication Critical patent/WO2011051948A2/fr
Publication of WO2011051948A3 publication Critical patent/WO2011051948A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
    • D06M11/32—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond
    • D06M11/36—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond with oxides, hydroxides or mixed oxides; with salts derived from anions with an amphoteric element-oxygen bond
    • D06M11/38—Oxides or hydroxides of elements of Groups 1 or 11 of the Periodic System
    • D06M11/42—Oxides or hydroxides of copper, silver or gold
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
    • D06M11/83—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with metals; with metal-generating compounds, e.g. metal carbonyls; Reduction of metal compounds on textiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • Alopecia refers to a condition which occurs as hairs in anagen are decreased and hairs in catagen and telogen are increased.
  • Hair loss is a common affliction of humans, the most typical being alopecia where males lose scalp hair with age (male pattern baldness).
  • Alopecia is mainly caused by excessive secretion of androgen, one of male sex hormones, in hair root and sebaceous gland, which intensively stimulates hair follicle cells and contracts hair follicles, thereby to retard hair growth.
  • Other known causes of alopecia include insufficient nutrition due to local blood flow disturbance, excessive secretion of sebum, malfunction of scalp due to peroxides, bacteria, etc., lapse of neurosis due to intensive external stress and chronic diseases, and so on.
  • alopecia in young age is increased including female obese alopecia as well as male pattern alopecia.
  • hair regrowth or growth agents have been commercialized for improving alopecia.
  • Commercially available hair regrowth or growth agents include vasodilators such as capronium chloride, minoxidil, etc., hormone drugs for inhibiting action of male sex hormone such as estrogen, estradiol, etc. and inhibitors of activity of male sex hormone such as pentadecanoic acid, finasteride, etc.
  • this invention provides a. composition for the stimulation or enhancement of hair growth in a subject, the composition being formulated for topical application and comprising an insoluble copper oxide as active ingredient therein.
  • this invention further provides a textile suitable as a hair covering for the stimulation or enhancement of hair growth in a subject, the textile comprising an insoluble copper oxide as active ingredient therein, wherein said copper oxide is incorporated within fibers of said textile.
  • this invention further provides a composition for the limitation or abrogation of hair loss in a subject, the composition being formulated for topical application and comprising an insoluble copper oxide as active ingredient therein.
  • the present disclosure relates to methods, products and compositions for the treatment and prevention of human hair loss and/or scalp conditions such as dandruff.
  • the present disclosure provides a composition comprising an effective amount of an insoluble copper oxide as active ingredient therein and a pharmaceutical excipient, diluent or carrier.
  • the present invention provides pharmaceutical compositions and textiles comprising effective amounts of an insoluble copper oxide as active ingredient therein for maintaining hair follicle cells longer in the anagen phase of the hair cycle, and in particular, for treating hair shedding and telogen effluvium by catagen inhibition.
  • the invention therefore encompasses pharmaceutical compositions and textiles comprising an insoluble copper oxide as active ingredient therein for treatment of chronic telogen effluvium, non-scarring alopecia, alopecia, hair loss, acute hair loss, non-scarring alopecia, balding.
  • the invention provides a pharmaceutical composition and/or textile comprising an effective amount of an insoluble copper oxide as active ingredient therein for inhibiting or diminishing dandruff.
  • the invention provides for the use of such compositions and/or textiles for the treatment of hair loss, or for the stimulation or enhancement of hair growth.
  • compositions comprising an insoluble copper oxide as active ingredient therein have been described to be potent wound healing agents, to date, there has been no positive effect specifically described for treating hair loss, or stimulating hair growth or treating dandruff.
  • present Application is directed to the novel aspect that compositions and/or textiles comprising an insoluble copper oxide as active ingredient therein are useful in treating hair follicles and thereby stimulating or enhancing hair growth and/or hair re-growth,
  • compositions and/or textiles comprising an insoluble copper oxide as active ingredient therein are useful in significantly maintaining hair follicles in anagen.
  • Telogen effluvium is a form of non-scarring alopecia characterized by diffuse hair shedding, often with an acute onset. Telogen effluvium can affect hair on all parts of the body, but, generally, only loss of scalp hair is symptomatic. Understanding the pathophysiology of telogen effluvium requires knowledge of the hair growth cycle. All hair has a growth phase, termed anagen, apoptosis-driven regression (catagen) and a resting quiescent phase, telogen (Paus et al., The biology of hair follicles, NEJM 1999, 341 -.491-497).
  • telogen On the scalp, anagen lasts approximately 3 years, while telogen lasts roughly 3 months, although there can be wide variation between individuals.
  • the resting hair remains in the follicle until it is pushed out by growth of a new anagen hair. In most people, 5-15% of the hair on the scalp is in telogen at any given time. Shedding does not occur until the new anagen hairs begin to grow. The emerging hairs help to force the resting hairs out of the follicle. Recent evidence suggests that the mechanism of shedding of a telogen hair is an active process that may occur independent of the emerging anagen hair.
  • telogen effluvium The symptom of both acute and chronic telogen effluvium is increased hair shedding and diffuse hair loss from the entire scalp. Acute telogen effluvium is defined as hair shedding lasting less than 6 months. Patients usually only complain that their hair is falling out at an increased rate or that the remaining hair feels less dense.
  • telogen effluvium and acute hair shedding can be physiologic stress, papulosquamous diseases of the scalp such as psoriasis and seborrheic dermatitis, allergic contact dermatitis, immunizations, severe infections (HIV), acute illness such as febrile illness, major surgery and severe trauma as well as chronic illness such as malignancy, particularly lymphoproliferative malignancy, systemic lupus erythematosus, end-stage renal disease, or liver disease, hormonal changes such as pregnancy and delivery (can affect both mother and child), hypothyroidism, discontinuation of estrogen- containing medications; changes in diet like crash dieting, anorexia, low protein intake, and chronic iron deficiency, heavy metals such as selenium, arsenic, and thallium.
  • papulosquamous diseases of the scalp such as psoriasis and seborrheic dermatitis, allergic contact dermatitis, immunizations, severe infections (HI
  • Medications of which the most frequency cited are beta-blockers, anticoagulants, retinoids (including excess vitamin A), propylthiouracil (induces hypothyroidism), carbamazepine, and immunizations.
  • this type of medication represents itself as a problem.
  • the hair is composed of a protein called keratin.
  • the hair itself is arranged in three layers, an outer cuticle, middle cortex and central medulla. Hair grows from a follicle.
  • the walls of the follicle form the outer root sheath of the hair.
  • the lower part of the follicle widens out to form the hair bulb that contains the germinal matrix, the source of hair growth.
  • Dermal tissue projects into the follicle base to form the dermal papilla, and this has a network of capillary blood vessels to supply oxygen, energy and the amino acids needed for growth.
  • an inner root sheath that has three layers surrounds the hair.
  • the Henle's layer is one cell thick and lies to the outer root sheath.
  • Huxley's layer is two or three cells thick and is in the middle of the sheath.
  • the cuticle of this inner root sheath interlocks with the cuticle of the hair.
  • Both the hair and the inner root sheath grow at the same rate, but the inner root sheath breaks down about two-thirds of the way up the follicle, so only the hair emerges past the skin surface. Uncut hairs have a pointed tip.
  • the present invention provides, in some embodiments, a pharmaceutical composition and/or textile that has immediate effect on the hair shedding.
  • the pharmaceutical compositions and/or textiles of this invention prevent hair shedding or promote hair growth or a combination thereof.
  • compositions and/or textiles of this invention on hair shaft production may be shown and tested via any number of means known in the art, for example, via the use of organ-cultured human scalp hair follicles (HF) under serum-free conditions, and evaluation of the insoluble copper oxide-treated hair follicles as to their persistence in anagen phase as compared to vehicle-treated control hair follicles.
  • HF organ-cultured human scalp hair follicles
  • the present disclosure provides an easy to use topical therapeutic composition and treatment for avoiding loss of hair.
  • the present disclosure provides a therapeutic composition for topical application for increasing the luster of hair.
  • a further embodiment in the present disclosure is represented by a treatment for hair loss through topical application of insoluble copper oxides in various formulations designed for topical application.
  • Another embodiment is represented by a treatment for hair loss through the wearing of a textile produce incorporating insoluble copper oxide therein.
  • compositions of the present invention may be formulated into a lotion, an ointment, a cream, a patch, a spray, a powder, a sachet, a suspension, an emulsion, a solution, or an oil.
  • the composition of the present invention may be used by directly spreading or spraying it.
  • Hairs to which the composition of the present invention is applied include hair root, hair follicle and hair on the head, eyebrows and eyelashes, beard, mustache, whiskers, auxiliary hair, as well as any regions of body having hair root and hair follicle. Therefore, the present invention may be used as hair tonic, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair conditioner, hair shampoo, hair rinse, hair pack, hair treatment, eyebrow regrowth agent, eyelash regrowth agent or nutrients for eyelashes, or shampoo and rinse for pet animals.
  • a dosage of copper oxide according to the present invention should be appropriately determined considering sex, age, condition of alopecia, condition of hair, etc. Generally, a daily dosage for an adult is about .01 to about 1 mg/cm 2 , which may be applied 1 to 5 times a day.
  • the invention provides a composition formulated for topical application comprising an insoluble copper oxide as active ingredient therein.
  • the copper oxide is cupric oxide and in some embodiments, the copper oxide is cuprous oxide and in some embodiments, the compositions and/or textiles of this invention may comprise both cupric and cuprous oxide.
  • the composition is a suspension comprising micronized copper oxide particles, which in some embodiments, have a size from about 0.5 - about 900 ⁇ , or in some embodiments, from about 200-lOOOOnm.
  • the composition comprises from about 0.1% to about 10% copper oxide w/w.
  • compositions of this invention will further comprise a suitable carrier, which carrier, in some embodiments, is adapted for topical administration to a subject.
  • the suitable carrier may comprise of at least one emollient.
  • the suitable carrier may be a skin penetrating carrier.
  • the skin penetrating carrier may be DMSO, liposomes, lipophilic solvents, lecithin, transcutol, melatonin, nanospheres, nanoshells, cerasomes, and/or rovisomes.
  • the skin-penetrating carrier comprises a hollow and solid lipid structure. In another embodiment, the skin-penetrating carrier comprises a nano- structure.
  • the suitable carrier is selected from the group consisting of a transdermal patch, lotion, ointment, paste, foam, emulsion, cream, serum, aerosol, spray, roll-on formulation, masque, cleanser, shampoo, conditioner, gel, oil or moisturizer,.
  • the suitable carrier can be a lubricating formulation, water-based formulation, silicone-based formulation, petroleum- based formulation, natural-oil based formulation, and/or massage formulation.
  • the composition further comprises at least one additional agent.
  • the said at least one additional agent can be selected from the group consisting of minerals, antimicrobial agents, antioxidants, antigens, analgesics, anti-inflammatory agents, sebum-reducing agents, hormones, enzymes, peptides, proteins, lipids, retinoids, vitamins, wound recovery agents, botanical extracts, MMP inhibitors, integument and skin-supporting components, or massage oils.
  • the composition further comprises an antimicrobial agent selected from the group consisting of triclosan, povidone, iodine, proflavine, honey, hydrogen peroxide, clotrimazole, or sulfur.
  • an antimicrobial agent selected from the group consisting of triclosan, povidone, iodine, proflavine, honey, hydrogen peroxide, clotrimazole, or sulfur.
  • the composition further comprises an antioxidant selected from the group consisting of beta glucan, curcumin, carnosine, polyphenolics, superoxide dismutase (SOD), catalase, glutathione peroxidase, oligomeric proanthocyanidins, bioflavonoids, oligomeric procyanidolic complexes, leuco anthocyanin, anthocyanidin, alpha-Iipoic acid, coenzyme Q-l 0, selenium, vitamin E, vitamin C, lycopene, tocotrienols, or glutathione.
  • an antioxidant selected from the group consisting of beta glucan, curcumin, carnosine, polyphenolics, superoxide dismutase (SOD), catalase, glutathione peroxidase, oligomeric proanthocyanidins, bioflavonoids, oligomeric procyanidolic complexes, leuco anthocyanin, anthocyanidin
  • the composition further comprises an analgesic comprising an amine-containing local anesthetic.
  • the composition further comprises an antihistamine analgesic.
  • the composition further comprises an analgesic selected from the group consisting of paracetamol, NSAIDs, benzocaine, butamben picrate, dibucaine, dibucaine hydrochloride, dimethisoquin hydrochloride, dyclonine hydrochloride, lidocaine, lidocaine hydrochloride, pramoxine hydrochloride, tetracaine, tetracaine hydrochloride, alcohols and ketones, benzyl alcohol, camphor, combinations of camphor and phenol, camphorated metacresol, juniper tar, menthol, phenol, phenolate sodium, resorcinol, antihistamines, diphenylhydramine hydrochloride, tripelennamine hydrochloride, hydrocor
  • composition according to the present invention further comprises anti-inflammatory agents selected from the group consisting of hyssop, licorice extract, aloe, salicylic acid, allantaoin, bisabolol, or fumaric acid.
  • anti-inflammatory agents selected from the group consisting of hyssop, licorice extract, aloe, salicylic acid, allantaoin, bisabolol, or fumaric acid.
  • the composition further comprises sebum-reducing agent selected from the group consisting of azelaic acid, revivogen, or MK-386 (4,7β- dimethyl- 4-aza-5a-cholestan-3 -one).
  • the composition further comprises a peptide selected from the group consisting of palmitoyl pentapeptide, ubiquitin, oligopeptide, neuropeptide Y, pentapeptide, hexapeptide, acetyl hexapeptide-3, palmitoyl pentapeptide 3, epidermal growth factor (Egf), copper and copper containing peptides, thrombin, or fibroblast growth factor (Fgf).
  • the composition further comprises a lipid selected from the group consisting of glycerides, phospholipids, phosphatidylcholine, or lecithin.
  • the composition further comprises a retinoid selected from the group consisting of tretinoin, retinol, rose hips, or 9-cis retinoic acid.
  • a retinoid selected from the group consisting of tretinoin, retinol, rose hips, or 9-cis retinoic acid.
  • some particular embodiments may further comprise vitamins wherein the said vitamin is selected from the group consisting of vitamin A, Bl, B2, B3, B5, B6, B7, B9, B12, C, Ester-C, D, E, F, or K.
  • Other embodiments may comprise vitamin containing compounds such as rose hips.
  • wound recovery agents selected from the group consisting of allantoin, beta glucan, geranium extract, azelaic acid, curcumin, fumaric acid, gamma linolenic acid, farsenol, or squalene.
  • the present invention provides for compositions comprising MMP inhibitors selected from the group consisting of minimal-domain MMPs, simple hemopexin domain-containing MMPs, gelatin-binding MMPs, furin-activated MMPs, and vitronectin-like insert MMPs, type I transmembrane MMPs, glycosyl-phosphatidyl inosital (GPI)-linked MMPs, or type II transmembrane MMPs.
  • MMP inhibitors selected from the group consisting of minimal-domain MMPs, simple hemopexin domain-containing MMPs, gelatin-binding MMPs, furin-activated MMPs, and vitronectin-like insert MMPs, type I transmembrane MMPs, glycosyl-phosphatidyl inosital (GPI)-linked MMPs, or type II transmembrane MMPs.
  • compositions comprising polysaccharides such as beta glucan or dextran.
  • some embodiments comprise integument and integument and skin- supporting components selected from the group consisting of vitamin K, borage oil, flax seed, cod liver oil, black currant, alpha and beta hydroxy acids, grape seed, pycnogenol, rose hips, sunscreens, tea tree oil, acetyl glucosamine algae, collagen, elastin, copper PCA, dead sea minerals, glycerin, hormone creams, human growth factor, kinetin, lanolin, mineral oil, olive oil, oxygen, perflurodecalin (Rejuvenox), soy lecithin phospholipids, hydrogen peroxide, triclosan, salicylic acid, papain, aloe vera, lavender oil, geranium oil, chamomile, calendula officinalis, squalane, magnesium oxide crystals, macademia nut oil, galactoarabinan, magnesium aluminum silicate, sweet almond oil, sesame oil, palmitoyl- pent
  • the composition comprises at least one additional agent selected from the group consisting of base components, surfactants, thickening agents, gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients, foaming agents, diluents, fillers, binding agents, or preservatives.
  • additional agent selected from the group consisting of base components, surfactants, thickening agents, gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients, foaming agents, diluents, fillers, binding agents, or preservatives.
  • the described components of the composition are encapsulated by a protective membrane.
  • the protective membrane can be a liposome, nanosphere, rovisome, cerasome, or nanoshell.
  • the protective membrane encapsulates a portion of the components.
  • a protective liposomal membrane encapsulates a portion of the components.
  • compositions of this invention will, in some embodiments, comprise pharmaceutically acceptable and/or suitable carriers
  • a "pharmaceutically acceptable,” “acceptable,” and/or “suitable” carrier includes any and/or all solvents, dispersion media, coatings, isotonic, and/or absorption delaying agents and/or the like.
  • the phrases “pharmaceutically,” “pharmacologically,” “suitable,” and/or “acceptable” refer to materials, substances, or compositions that do not produce an adverse, allergic or other untoward reaction when administered to a subject. The selection and use of such materials may be readily determined by one of skill in the art.
  • Carriers can optionally include one or more components which can be biologically active or inactive.
  • optional inactive components include base components (e.g., water, propylene glycol, glycerol, polyethylene glycols, silicones, and/or an oil, such as liquid paraffin, vegetable oil, peanut oil, castor oil, and cocoa butter), surfactants, thickening agents (e.g., aluminum stearate and hydrogen lanolin), gelling agents, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, humectants, emollients, acidic or alkaline substances, buffering agents, anti-crystalline agents, lubricating agents, coloring agents, perfumes, excipients (e.g., starch, tragacanth, and cellulose derivatives), foaming agents, diluents, fillers, binding agents, and preservatives (e.g., methyl paraben, propyl paraben, methylchloroiso
  • base components
  • the carrier may comprise capsules suitable for depositing actives, fragrances, color, glitter etc. onto the skin and integument.
  • Capsules suitable for deposition include, for example, capsules made from mannitol, lactose cellulose, and hydroypropylmethylcellulose. Suitable capsules are, for example, marketed using the Unispheres process of Inducehm, Dubendorf, Switzerland.
  • the present invention also provides for skin-penetrating or skin- permeating carriers.
  • skin-penetrating or skin- permeating carriers include, for example, DMSO, liposomes, lipophilic solvents, lecithin, transcutol, nanospheres, nanoshells, and rovisomes.
  • the insoluble copper oxides of the compositions are encapsulated in a protective membrane structure.
  • the protective membrane structure can be, for example, a hollow and solid lipid structure, nanoshell, nanosphere, cerasome, rovisome, or nano-structure.
  • the encapsulating protective structure is a liposome.
  • a liposome is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes may be characterized as having vesicular structures with a bilayer membrane, generally comprising a phospholipid, and an inner medium that can comprise an aqueous composition.
  • some or all of the components of the present invention may be encapsulated in the interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with the liposome, entrapped in a liposome, complexed with a liposome, etc.
  • the size of a liposome varies depending on the method of synthesis. Liposomes in the present invention can be a variety of sizes. In preparing such liposomes, any protocol as would be known to one of ordinary skill in the art may be used.
  • Protegenetic liposome or “Protegenetic liposome complex” generally refers to some embodiments of the present invention, wherein a protective liposomal membrane encapsulates some or all of the components in the skin and integument compositions described.
  • more than one protective membrane may be used.
  • the composition of the present invention comprises a first protective membrane encapsulating one or more components of the composition and a second protective membrane encapsulating the first protective membrane and additional components not encapsulated by the first protective membrane.
  • the composition comprises a first protective membrane encapsulating one or more components of the composition and at least one additional protective membrane encapsulating one or more components of the composition. Regardless of whether a single or multiple protective membranes are used, each individual membrane can be designed to encapsulate a portion of the components of the composition or all components of the composition.
  • the described composition comprises carrier components useful for topical application to skin, integument, and mucosal membrane.
  • This composition can be, for example, a cream, ointment, lotion, cosmetic, soap, wash, shampoo, conditioner, rinse, hair tonic, hair spray, hair dye, hair care treatment, scalp treatment, pain relief spray, facial spray, roll-on formulation, masque, cleanser, moisturizer, and composition-containing pad, patch, strip, or bandage etc.
  • the topical formulation can include other ingredients such as humectants that reduce the rate at which the cream or lotion dries out.
  • topical compositions can be formulated, whereby such compositions are stimulatory for hair growth, and such effect can be seen, even in the absence of a wound in or at a nearby region of the skin being thus treated.
  • the invention therefore provides, in some embodiments, a topical composition comprising an insoluble copper oxide as active ingredient therein, wherein said composition comprises from about 0.01% to about 10% copper oxide w/w.
  • the present invention provides for a topical cream composition
  • a topical cream composition comprising Water, Octyldodecanol.
  • the present invention provides for a masque composition
  • a masque composition comprising at least one component selected from the group consisting of water, sodium magnesium silicate, glycerin, mica, titanium dioxide, polyquaternium-7, hydroxyethyl urea, polyacrylamide, C13-14 isoparaffin, laureth-7, immortelle essential oil, colloidal gold, dipalmitoyl hydroxyproline, tetrahexyldecyl ascorbate, C12- 15 alkyl benzoate, tribehenin, ceramide II, PEG-40 rapeseed sterol, palmitoyl oligopeptide, bismuth oxychloride, magnesium sulfate, calcium carbonate, zinc oxide, propylene glycol, methylparaben, propylparaben, potassium sorbate, and fragrance.
  • the masque composition comprises components of a percentage by weight listed below: Water from about QS to 100.00% Sodium Magnesium Silicate from about 2.0 - 10.00% Glycerin from about 1.0 - 10.00% Mica from about 0.05 - 3.000% Titanium Dioxide from about 0.05 - 5.000% Polyquaternium-7 from about 0.05 - 1.000% Hydroxyethyl Urea from about 0.05 - 5.000% Polyacrylamide from about 0.05 - 0.500% C13-14 Isoparaffin from about 0.10 - 1.000% Laureth-7 from about 0.05 - 1.000% Helichrysum Angustifolium (Immoretelle) Extract from about 0.001 - 1.00% Colloidal Gold from about 0.001 - 1.00% Dipalmitoyl Hydroxyproline from about 0.001 - 1.00% Tetrahexyldecyl Ascorbate from about 0.001 - 1.00% C12-15 Alkyl Benz
  • the masque composition comprises components of a percentage by weight listed below: Water A Sodium Magnesium Silicate C Glycerin C Colloidal Gold (24K) D Mica (Gold) E Titanium Dioxide E Polyquaternium-7 E Hydroxyethyl Urea E Polyacrylamide E C13-14 Isoparaffϊn E Laureth-7 E Helichrysum Angustifolium (Immortelle) Extract E Bismuth Oxychloride E Ricinus Communis (Castor) Seed Oil E Phenoxyethanol E Ethylhexylglycerin E Dipalmitoyl Hydroxyproline F Tetrahexyldecyl Ascorbate F Fragrance F Magnesium Sulfate F Calcium Carbonate F Zinc Oxide F Composition Legend A: from about 30% to about 100% B: from about 10% to less than about 30% C: from about 3% to less than about 10% D: from about 1% to less than about 3% E: from about
  • the masque composition further comprises Protegenetic liposomes.
  • the Protegenetic liposomes comprise from about 0.01 - 1.0 percent by weight of the composition.
  • the present invention provides for a serum composition
  • a serum composition comprising at least one component selected from the group consisting of cyclopentasiloxane, dimethicone, vinyl dimethicone copolyol crosspolymer, immortelle essential oil, colloidal gold, gold leaf, dipalmitoyl hydroxyproline, and tetrahexyldecyl ascorbate.
  • the serum composition comprises components of a percentage by weight listed below: Cyclopentasiloxane from about QS to 100.00% Dimethicone/Vinyl Dimethicone Crosspolymer from about 0.01 - 50.0000% Helichrysum Angustifolium (Immortelle) Extract from about 0.0001 - 1.000% Colloidal Gold from about 0.0001 - 2.000% Gold leaf from about 0.0001 - 1.000% Dipalmitoyl Hydroxyproline from about 0.0010 - 1.000% Tetrahexyldecyl Ascorbate from about 0.0010 - 1.000%
  • the serum composition comprises components of a percentage by weight listed below: Cyclopentasiloxane A Dimethicone/Vinyl Dimethicone Crosspolymer C Helichrysum Angustifolium (Immortelle) Extract F Gold Leaf (CI 77480) F Dipalmitoyl Hydroxyproline F Tetrahexyldecy] Ascorbate F Colloidal Gold (24 K) F Composition Legend A: from about 30 to about 100% B: from about 10% to less than about 30% C: from about 3% to less than about 10% D: from about 1% to less than about 3% E: from about 0.1% to less than about 1% F: less than about 0.1%
  • the serum composition further comprises Protegenetic liposomes.
  • the Protegenetic liposomes comprise from about 0.01 - 1.0 percent by weight of the composition.
  • the invention provides a textile suitable as a hair covering for the stimulation or enhancement of hair growth in a subject, the textile comprising an insoluble copper oxide as active ingredient therein, wherein the copper oxide is incorporated within fibers of the textile.
  • the invention provides a textile suitable as a hair covering for the limitation or abrogation of hair loss in a subject, said textile comprising an insoluble copper oxide as active ingredient therein, wherein said copper oxide is incorporated within fibers of said textile.
  • the textile comprises cellulose fibers or yarns comprising the copper oxide.
  • the textiles and/or compositions of this invention are prepared as exemplified herein or by modification of what is exemplified herein, by standard methodology as will be appreciated by the skilled artisan..
  • the textiles of this invention may be prepared as described in United States Patent Application Publication Serial No. 2009001096; 20080311165; 20080241530; United States Patent No. 6,482,424; and World Intellectual Property Organization Publication No. WO 06/051529, all of which are fully incorporated by reference herein.
  • the textile may be incorporated within any head covering or skull cap, or an inner lining of any head covering.
  • the textile may be incorporated within or configured to assume or form a cap or bonnet, kerchief, scarf, beret, bandana, turban, hat, patch or large bandage which may be affixed to the scalp or head of the subject treated thereby.
  • the head covering may comprise a gentle elastic or adhesive, for proper orientation and affixation on the scalp or head of the subject treated thereby.
  • the present invention also relates to methods of administering any of the described compositions and/or textiles for the treatment and prevention of hair loss and/or scalp conditions and diseases.
  • the invention provides a composition for the reduction or abrogation of dandruff in a subject, said composition being formulated for topical application and comprising an insoluble copper oxide as active ingredient therein.
  • the invention provides a textile suitable as a hair covering for the limitation or abrogation of dandruff in a subject, said textile comprising an insoluble copper oxide as active ingredient therein, wherein said copper oxide is incorporated within fibers of said textile.
  • compositions of the present invention can be administered to any suitable subject, including animals, humans, and other organisms. In the context of animals, the compositions of the present invention can also be used for veterinary administration to any suitable animal subject such as, for example, cats, dogs, or horses.
  • the invention provides, in various embodiments, all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
  • elements are presented as lists, e.g. in Markush group format or the like, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
  • Textiles comprising insoluble copper oxides are prepared as described, for example in United States Patent Application Publication Serial No. 20080311165, 20080311165, World Intellectual Property Organization Patent Application Publication No. WO 06/051529; WO 08/117277; or WO 06/048879, and others, as will be appreciated by the skilled artisan.
  • the textiles may be fashioned into a sleeping cap or hair covering, which facilitates access of the scalp and other desired skin regions to the insoluble copper oxides to stimulate and/or enhance hair growth in subjects treated thereby.
  • Other means for generating textiles for use in accordance with this invention may comprise plating of either a cellulose fiber or a textile made of some or all cellulosic yarns.
  • the method may include adaptation of electrolyses plating of plastics, particularly printed circuit boards made of plastic, with metals. See, for example, Encyclopedia of Polymer Science and Engineering (Jacqueline I. Kroschwitz, editor), Wiley and Sons, 1987, vol. IX, pp 580-598.
  • this process includes two steps: a first step of activating the fiber or textile by precipitating catalytic noble metal nucleation sites onto the fiber or textile, which may be accomplished by first soaking the loose fibers or textile in a solution of a low-oxidation-state reductant cation, and then soaking the textile in a solution of noble metal cations, for example, in a solution of Pd ++ cations, or for example, in an acidic PdCl 2 solution.
  • the low-oxidation-state cation reduced the noble metal cations to the noble metals themselves, while being oxidized to a higher oxidation state.
  • the reductant cation was one that was soluble in both the initial low oxidation state and the final high oxidation state, for example Sn ++ , which is oxidized to Sn ++++ , or Ti +++ , which was oxidized to Ti ++++ .
  • the second step included the reduction, in close proximity to the activated textile, of a metal cation whose reduction was catalyzed by a noble metal.
  • the reducing agents used to reduce the cations typically are molecular species, for example, formaldehyde in the case of Cu ++ . Because the reducing agents are oxidized, the metal cations are termed "oxidant cations".
  • the metallized textiles thus produced are characterized in that their metal plating was bonded directly to the textile fibers.
  • This process can conducted on a textile which can be used for a direct dermal application or can be applied to cotton or cellulosic fibers that can then be introduced into a yarn and converted to a textile.
  • Another method for textile preparation may include using impregnated polymers that include synthetic fibers, injection molded materials and extruded materials including a materials in the form of a sheath and non-woven textile products made from synthetic materials for application directly to the scalp/skin
  • the textile may be prepared according to the following method: a slurry is prepared from any polymer, for example, a polyamide, a polyalkylene, a polyurethane and a polyester.
  • the polymeric raw materials are usually in bead form and can be mono-component, bi-component or multi-component in nature.
  • the beads are heated to melting at a temperature which preferably will range from about 120 to 180 °C.
  • a water insoluble powder of cationic copper oxide is added to the slurry after being treated with a surfactant and dispersing agent and allowed to spread through the heated slurry.
  • the particulate size will be preferably between .01 and 10 microns, however can be larger when the film or fiber thickness can accommodate larger particles.
  • the liquid slurry is then pushed with pressure through the holes of a spinneret in the case of a fiber, through an extruder in the case of a sheath or film, or a mold in the case of an injection molded object.
  • a spinneret in the case of a fiber
  • an extruder in the case of a sheath or film
  • a mold in the case of an injection molded object.
  • the hot liquid fiber or film is pushed upward with cold air forming a continuous series of fibers or a circular sheet.
  • the thickness of the fibers or sheet is controlled by the size of the holes and speed at which the slurry is pushed through the holes and upward by the cooling air flow.
  • Another method for the generation of a textile for use in accordance with this invention includes the incorporation of recycled cellulose fibers and pulp into a textile yarn or applied directly to the skin.
  • One process for manufacturing viscose rayon or other recycled cellulose based materials may include (1) Steeping, (2) Pressing, (3) Shredding, (4) Aging, (5) Xanthation, (6) Dissolving, (7) Ripening, (8) Filtering, (9) Degassing, (10) Spinning, and (11) Stretching or Drawing, where copper oxide particles of up to 3 microns in diameter may be added prior to the (10) spinning step, in one embodiment of this aspect.
  • copper oxide powder is added in the "dissolving" step, and in one embodiment, the addition is conducted in the final stage of dissolving, which involves a mixing process, which may limit the exposure of the powder to the acid used in the process of manufacturing viscose/rayon.
  • Another method for the generation of a textile for use in accordance with this invention includes the incorporation of insoluble copper oxide within woven or knit textiles which can be applied directly to the skin, where the textile is formed from fibers or yarns as herein described, for example, where insoluble copper oxide impregnated staple polymer is mixed with the cotton or other fibers and is spun in the fashion of normal staple fibers for the production of a yarn. That yarn is then knit or woven as part of the fabric in the same fashion in which a normal fabric would be produced.
  • One means for maintaining such reservoir is by maintaining the insoluble copper oxide in a segregated compartment, for example via encapsulation of the copper oxide particles, or by partitioning within an emulsion, for example as a solid-in-oil or solid-in-oil-in-water emulsion.
  • the encapsulation formulations or partitioned formulations have a triggered release mechanism, which facilitates release of the partitioned insoluble copper oxide, for example, by formulating in a wax composition which melts at a desired temperature, such as that of skin contact with the formulation as opposed to room or the storage temperature of the formulation.
  • the encapsulant can be so constructed so as to release the copper oxide in the presence of a desired physical pressure.
  • encapsulant release may be a function of time.
  • Micronized Copper Oxide is formulated into an oil-in- water-based emulsion.
  • a useful formulation consists of lipids, silicones, derivatives, emulsifiers, preservatives, and the copper oxide.
  • a representative composition is as tabulated below: By Weight Silicones 20 Behenyl
  • the control of the release of ions as well as the retention of the ions is maintained when the physical copper oxide particle is encapsulated.
  • the material encapsulating the copper oxide particle needs to be ruptured so that as much as possible the ions will penetrate the dermal layers to stimulate the necessary biological mechanisms for hair growth.
  • the topical preparation is prepared as follows: [00106] A cuprous oxide powder is prepared, which is at least 95% pure. The powder size is approximately 1 micron in size. The powder is, in some embodiments, encapsulated so that it retains its ionic reservoir.
  • the carrier can be a cream, a paste, a foam, or a liquid of varying viscosity.
  • the encapsulant has a mechanism for release so that the active ingredient is only released into the carrier on demand.
  • an encapsulant in a cellulose based material which is very hard at its onset but softens over time when placed in the carrier would be one embodied formulation method. The cellulose starts out very hard but softens with time. Eventually, one can release the active ingredient from the encapsulant through gentle pressure of the hands because the cellulose softens over time but does not disintegrate or allow the active ingredient to be exposed to the aqueous carrier until crushed.
  • An example of this technology would be the system used by Tagra Ltd. of Israel.
  • the encapsulant can be one that uses a heat sensitivity mechanism for release of the active ingredient using paraffin or other wax products.
  • the encapsulant may operate based on a pressure-release mechanism, for example, by applying pressure thereto, for example, when the encapsulate is a hard encapsulating material such as a silicone.
  • Sponge or foam formulations containing insoluble copper oxide are appropriate in accordance with the subject invention, as well.
  • a copper oxide powder is added to the appropriate excipients which, in the example of a polyurethane foam, can be either the isocyanate or hydroxyl components before mixing them together to get the desired foam forming reaction.
  • Powder formulations of insoluble copper oxide may be used, as well. Formulation is straightforward, by any of the known methods in the art and as described herein.
  • Animal models such as the Dundee experimental bald rat (DEBR) model (Br J Dermatol. 1991 Aug;125(2):94-100) are used to evaluate the formulations of the subject Application, in comparison to control formulations lacking insoluble copper oxide. Animals are treated with any of the formulations of the invention and hair growth as a consequence of time and dosage of treatment is evaluated.
  • DEBR Dundee experimental bald rat

Abstract

L'invention concerne des compositions topiques et des textiles destinés à entrer en contact avec la peau pour stimuler ou améliorer la croissance capillaire d'un individu utilisant ceux-ci, les compositions et textiles contenant un oxyde de cuivre insoluble en tant qu'ingrédient actif. L'invention concerne aussi l'utilisation de ces compositions et textiles pour limiter ou supprimer la perte de cheveux ou stimuler la croissance capillaire chez un individu.
PCT/IL2010/000903 2009-11-02 2010-11-01 Compositions de soins capillaires et matériaux WO2011051948A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL201,884 2009-11-02
IL201884A IL201884A0 (en) 2009-11-02 2009-11-02 Hair care compositions and materials

Publications (2)

Publication Number Publication Date
WO2011051948A2 true WO2011051948A2 (fr) 2011-05-05
WO2011051948A3 WO2011051948A3 (fr) 2012-07-05

Family

ID=42335572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/000903 WO2011051948A2 (fr) 2009-11-02 2010-11-01 Compositions de soins capillaires et matériaux

Country Status (2)

Country Link
IL (1) IL201884A0 (fr)
WO (1) WO2011051948A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046229A3 (fr) * 2010-10-04 2013-07-04 Cupron Inc. Compositions cosmetiques de soin de la peau
US9403041B2 (en) 2004-11-09 2016-08-02 Cupron Inc. Methods and materials for skin care
WO2017189946A1 (fr) * 2016-04-29 2017-11-02 The Procter & Gamble Company Procédé de traitement d'une affection capillaire avec des n-hydroxypyridinones
US10537108B2 (en) 2015-02-08 2020-01-21 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
US10736398B2 (en) 2016-12-12 2020-08-11 The Procter And Gamble Company Apparatus and method for pulling a strand of hair
US11224227B2 (en) 2015-02-08 2022-01-18 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482424B1 (en) 1996-08-09 2002-11-19 The Cupron Corporation Methods and fabrics for combating nosocomial infections
WO2006048879A1 (fr) 2004-11-07 2006-05-11 The Cupron Corporation Materiaux contenant du cuivre pour le traitement des blessures, des brulures et d'autres etats cutanes
WO2006051529A1 (fr) 2004-11-09 2006-05-18 The Cupron Corporation Methodes et matieres pour les soins de la peau
US20080241530A1 (en) 2007-03-28 2008-10-02 The Cupron Corporation Antimicrobial, Antifungal and Antiviral Rayon Fibers
US20090001096A1 (en) 2004-11-09 2009-01-01 3M Espe Ag Method of Mixing and Extruding Viscous Materials and Gearbox for Dispensing the Same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177061A (en) * 1985-02-08 1993-01-05 Procyte Corporation Method for stimulating hair growth using GHL-Cu complexes
JP2003503333A (ja) * 1999-06-25 2003-01-28 ザ、プロクター、エンド、ギャンブル、カンパニー 局所用抗菌組成物
JP2008536949A (ja) * 2005-05-03 2008-09-11 ザ プロクター アンド ギャンブル カンパニー ケラチン繊維に適用するための離散粒子凝集体及び／又は粒塊を含む組成物
WO2008004184A2 (fr) * 2006-07-06 2008-01-10 The Procter & Gamble Company Composition de désodorisant comprenant un agent désodorisant métallique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482424B1 (en) 1996-08-09 2002-11-19 The Cupron Corporation Methods and fabrics for combating nosocomial infections
WO2006048879A1 (fr) 2004-11-07 2006-05-11 The Cupron Corporation Materiaux contenant du cuivre pour le traitement des blessures, des brulures et d'autres etats cutanes
US20080311165A1 (en) 2004-11-07 2008-12-18 The Cupron Corporation Copper Containing Materials for Treating Wounds, Burns and Other Skin Conditions
WO2006051529A1 (fr) 2004-11-09 2006-05-18 The Cupron Corporation Methodes et matieres pour les soins de la peau
US20090001096A1 (en) 2004-11-09 2009-01-01 3M Espe Ag Method of Mixing and Extruding Viscous Materials and Gearbox for Dispensing the Same
US20080241530A1 (en) 2007-03-28 2008-10-02 The Cupron Corporation Antimicrobial, Antifungal and Antiviral Rayon Fibers
WO2008117277A2 (fr) 2007-03-28 2008-10-02 The Cupron Corporation Fibres de rayonne antimicrobiennes, antifongiques et antivirales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Polymer Science and Engineering", vol. IX, 1987, WILEY AND SONS, pages: 580 - 598
BR J DERMATOL., vol. 125, no. 2, August 1991 (1991-08-01), pages 94 - 100
PAUS ET AL., THE BIOLOGY OF HAIR FOLLICLES, NEJM, vol. 341, 1999, pages 491 - 497

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403041B2 (en) 2004-11-09 2016-08-02 Cupron Inc. Methods and materials for skin care
US9931283B2 (en) 2004-11-09 2018-04-03 Cupron Inc. Methods and materials for skin care
WO2012046229A3 (fr) * 2010-10-04 2013-07-04 Cupron Inc. Compositions cosmetiques de soin de la peau
US10537108B2 (en) 2015-02-08 2020-01-21 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
US10667521B2 (en) 2015-02-08 2020-06-02 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
US11224227B2 (en) 2015-02-08 2022-01-18 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
WO2017189946A1 (fr) * 2016-04-29 2017-11-02 The Procter & Gamble Company Procédé de traitement d'une affection capillaire avec des n-hydroxypyridinones
US10543157B2 (en) 2016-04-29 2020-01-28 The Procter And Gamble Company Method of treating a hair disorder with N-hydroxypyridinones
US10736398B2 (en) 2016-12-12 2020-08-11 The Procter And Gamble Company Apparatus and method for pulling a strand of hair

Also Published As

Publication number Publication date
IL201884A0 (en) 2010-06-30
WO2011051948A3 (fr) 2012-07-05

Similar Documents

Publication Publication Date Title
EP2624806B1 (fr) Compositions cosmetiques de soin de la peau
US10953220B2 (en) Device and method of skin care and treatment via microneedles having inherent anode and cathode properties, with or without cosmetic or pharmacological compositions
US20100055138A1 (en) Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
US8017138B2 (en) Composition and method for treating skin
EP2218447A1 (fr) Compositions contenant des micro ou nanoparticules lipides pour l'amélioration de l'action dermique de particules solides
US20070086972A1 (en) Hair growth compositions and methods for treating hair loss or related conditions
JP2002544217A (ja) フィトステロール組成物の局所適用による哺乳動物ケラチン組織の状態の調整方法
MX2007013571A (es) Composiciones para el cuidado personal que contienen un dipeptido.
US20070081968A1 (en) Agent for inducing hair growth containing extracts of saw palmetto and swertia
JP2002542178A (ja) スキンケア活性物質の組合せを含有するスキンケア組成物
JP2005503335A (ja) 糖アミンを含有するスキンケア組成物
CA2516500A1 (fr) Regulation de la croissance des poils chez les mammiferes
WO2011051948A2 (fr) Compositions de soins capillaires et matériaux
HU230156B1 (hu) Hagymakivonatot és zsírolajat tartalmazó szer előállítása károsodott bőrszövet, különösen sebhelyek ellátására, megelőzésére vagy kezelésére
JP2002542177A (ja) 哺乳類のケラチン性組織の状態を調節する方法
CA2713041A1 (fr) Compositions ameliorees destinees a sublimer le teint
US7189406B1 (en) Composition and method for treating skin
US20070172431A1 (en) Methods, systems and compositions for skin care
PL214285B1 (pl) Zastosowanie kompozycji zawierajacej rosline portulaka do poprawy estetycznego wygladu skóry
CA2814676A1 (fr) Utilisation d'inhibiteurs de monoamine oxydase pour ameliorer la biologie epitheliale
US5520919A (en) Vitamin A palmitate composition and methodology for repairing and rejuvenating human skin
JP2002542179A (ja) スキンケア活性物質の組合せを含有するスキンケア組成物
KR101053471B1 (ko) 기능성 물질을 포집한 고형왁스 마이크로캡슐의 제조방법 및 이를 함유하는 화장료 조성물
TW201808261A (zh) 皮膚照護產品及其用途
US20110262506A1 (en) Topical compositions containing coated active agents

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21.09.2012)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790792

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10790792

Country of ref document: EP

Kind code of ref document: A2